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PSORALEN PROPHYLAXIS AGAINST SKIN CANCER: PROGRESS OF FIELD
TRIALS *
CARL E. HOPKINS, Ph.D., M.P.H.
Selection of a rational strategy of research in
areas of knowledge potentially susceptible of
exploitation for immediate human welfare poses
a difficult choice between basic and applied
approaches. In early stages of research so little
may be known of the problem that no easy
decision can be made between the alternatives
of working methodically along lines indicated
by the fundamental theory such as it is, or making
bold hunch-inspired strikes for immediate practi-
cal applications. In medical research today the
pressures for the latter course are impressive
and brilliant advances in empirical therapy not
infrequently forerun fundamental theory and
knowledge.
Disappointing results in early empirical
efforts to confirm impressions of clinical useful-
ness of the psoralen compounds led us to shift
our major effort toward fundamental research in
basic mechanisms of photodynamie response of
the skin, using these compounds as a specially
helpful mode of entry into the problem, rather
than as the problem itself. Simultaneously,
as practical uses have been suggested by our
basic researches, we have allocated some part
of our resources to empirical investigations in
human subjects. Each of these programs has
enriched and advanced the other.
By the summer of 1956 a hypothesis of practical
significance had emerged from our experimenta-
tion with the psoralens: daily administration of
psoralens by mouth will afford susceptible
persons some protection against actinie skin
cancer. The observations and considerations
leading to this hypothesis were:
1. Patients using methoxsalen for vitiligo
treatment reported (testimonials) "protection"
against sunburn in the normal and especially
in the depigmented areas of their skin (1).
2. Controlled experiments (2) showed the pri-
mary effect of methoxsalen whether taken
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topically or orally to be potentiation of the skin
in its erythema and pigmentation responses to
ultraviolet irradiation.
3. Thickening of the stratum corneum was also
noted clinically in subjects using methoxsalen
with sunlight, but this effect was not studied in
our controlled experiments.
4. Informal experiments confirmed the earlier
noted observations (3, 4) that the stratum
corneum, entirely apart from pigmentation, can
occlude a large part of the incident ultraviolet
energy.
5. The apparent protective effect of psoralen
against sunburn could thus be explained as a
secondary result of increased activity of the
skin in raising its normal defenses, which then
become effective against subsequent ultraviolet
irradiation. Experiments done in Oregon in 1955—
56 tended to confirm this secondary protection,
but did not in their design distinguish the rela-
tive protective roles of increased pigmentation
and increased eorneal thickening (5).
6. Experiments by Griffin and O'Neal (6)
with ultraviolet-induced skin cancers in albino
mice showed a slower rate of tumor induction
in mice given methoxsalen in their diet than in
controls or in mice given daily intraperitoneal
injections of methoxsalen. Dosage calculations
suggested that the principal difference between
the intraperitonal and the dietary psoralens
might be quantitative, the intraperitoneal
representing a rather high effective dose to the
skin, the dietary a low dose. This experiment
was accordingly interpreted as meaning that in
the intraperitoneally treated mice the high dose
of psoralens had augmented skin responses to
ultraviolet irradiation beyond physiologically
tolerable levels, causing trauma and subsequently
triggering malignant growth; whereas in the
mice treated by the dietary route the low dose
had been sufficient to stimulate increased normal
protective responses of the skin against the
carcinogenic action of the subsequent irradiation.
Since the exact mechanism was not known for
either the psoralen activity or the careinogenesis
it was not possible to specify how this secondary
protective effect might be operating, but since
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the mice were albino, it was assumed that at
least the pigment factor could be ruled out as
having a role in the protective effect in these
mice.
7. A few patients using methoxsalen for routine
protection against solar radiation reported
reduced frequency of keratoses on exposed
surfaces. (Personal communication, T. B. Fitz-
patrick).
8. Epidemiologic surveys (7, 8) based on cancer
registries brought out that skin cancers are
more prevalent
(a) among light skinned than among dark
skinned people,
(b) in high, dry, sunny than in less sunny
climes, and
(e) on exposed surfaces of head, neck and
hands than elsewhere on the body.
These several facts and considerations led to
the hypothesis that at least some skin cancers
are etiologically related to the trauma of low
grade sunburn repeated over a long period.
Whether the final triggering of the neoplastic
strain of cells is related directly to ultraviolet
irradiation as such or indirectly through the
traumatic effects of irradiation, an agent that
would shield the skin from ultraviolet rays
might inhibit or delay the kick-off of the neo-
plastic process. While psoralen was no longer
believed to afford any primary shielding in the
sense of a simple sunscreen, we believed that at
low dose levels it would, without causing trauma,
increase physiological pigmentation and possibly
cornification of the epidermis sufficiently to
filter out a significantly increased amount of
ultraviolet energy. A small daily dose of oral
psoralen for a man working out of doors would
thus be equivalent to wearing a hat or applying
a protective cream to exposed parts of the
skin.
Other studies (9) had demonstrated low
toxicity and good human tolerance of methox-
salen used in this manner. While much was still
poorly understood, we felt that in cancer protec-
tion efforts some risks were acceptable. Thus
we were ready to contemplate a large scale
field trial of the prophylaxis hypothesis.
The Field Trial Plan. Since prophylactic
effects, like eareinogenesis itself, might be related
to very long-term cumulative agencies or to
relatively quick-acting trigger mechanisms, we
decided to look first for the latter possibility,
but to set up the study in such a way that later,
with long follow up, the latent effects might also
be examined. It was clear then that we needed
a number of persons of demonstrated ability
to produce skin cancers and aetinic keratoses who
would take the psoralen drugs faithfully and
report back for examination at regular intervals.
Because of ignorance of possible latent and
carryover effects we decided against using
subjects as their own controls and instead to
subdivide our study group into two contrasting
treatment groups.
A community was located in which a good
cancer registry showed high incidence of skin
cancer, with some 1500 living cases on the
register. It also happened to he a high, dry,
sunny locale inhabited by two contrasting
dermatologie families, one lightly and the other
rather darkly pigmented. A small group of
dermatologists who see a large proportion of the
skin affections of the locale volunteered to con-
duct a trial study under our direction. We sup-
plied the drugs, special study forms, and most
important of all, a clerk to work in their offices,
interviewing the patients, recording the data,
dispensing the drugs, monitoring the follow up,
and generally assuming the innumerable small
extra burdens imposed by a study. It cannot
be overemphasized that the success of a clinical
trial depends on provision of effective staff work
of this sort.
All patients who have had two or more skin
cancers or keratoses on head, neck or hands and
are willing to enter the study are admitted. Once
admitted they are given a study number and
study interview which includes inventory, with
photographs, of all lesions present, and skin
color readings on the reflectance meter. rrhey are
given a three-month supply of psoralen pills and
instructions for their use. At three-month inter-
vals they return for examination by the phy-
sician, follow up interview and photos, and refill
of their pill supply.
Control of the drug effect is obtained by use of
two different psoralen compounds which if our
hypothesis is even approximately correct will pro-
duce distinctly different prophylactic effects.
The two drugs are allocated to the patients indi-
vidually and blindly according to a prearranged
drawing of random numbers. They are supplied
by the manufacturer in identical appearing
bottles and capsules bearing only the general
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"psoralen" name and the name and number of
the patient. Only when our analysis of the results
has been completed and our conclusion drawn
will we decode and relate effects to the specific
drugs. The patients arc all told that they arc
being given a new drug which may cause in-
creased tanning and possibly prevent sunburning
and skin cancers. They take 20 mg. daily at
breakfast time.
Criterion of effect will be number of new
lesions occurring during each trial period (three
months). It is expected that about half of the
patients will produce new lesions in a given
period. Patients on the two contrast drugs will be
paired randomly and analysed sequentially fol-
lowing the Bross (10) plan for detection of a
moderate difference. This plan guarantees a good
chance of detecting a true difference of as much
as 25 percentage points, e.g. 50% vs. 25% having
new lesions, between the two treatment groups.
The sequential plan gives us a 95% chance of
detecting an adverse effect and a 90% chance of
detecting a prophylactic effect if such exist, and
permits us to stop the trial as soon as such an
effect becomes evident.
For this part of the trial, the immediate
effects part, we anticipate following about 500
patients for two years. To initiate studies of
latent effects we have provided for 100 of the
patients to be selected at entry into the study as
long-term ers who will stay in a continued study
for 5 years or more. By comparing their new
lesion rates in their first, second, third and up to
20th three-month period we hope to get informa-
tion on latent and cumulative effects of the drugs.
To the end of February 1958 we have admitted
118 patients to the study, distributed as shown
in Table 1. We don't know, of course, what is
the distribution of the two drugs, but our ran-
domizing plan assures that it is close to half
and half.
Difficulties encountered to date have not been
serious. Refusals have been negligible. With-
drawals (drop out) were high at first, seemed
related mainly to claims of nausea from use of
the drug. We may have solved this one by in-
structing the interviewer to refrain from suggest-
ing that there might be any such side effects.
Female subjects appear to be difficult to obtain
and to hold in the study. We may be unable to
make a sex breakdown in our final analysis. It is
conspicuous that many of these patients who are
Male Female All
Now in the first trial
period
second
third
fourth
Dropped out (in first
period)
42
33
14
1
5
9
6
3
0
5
51
39
17
1
10
95 23 118
TABLE 2
Distribution of Patients by Number of
New Lesions Observed
.Number of New Lesions
After First
Period
Drug A Drug B
After Second
Period
Dmg A Drug B
0
I
2
3andmore
28
3
1
3
35
25
1
1
2
29
9
3
1
0
13
12
2
0
1
15
Per cent with new
lesions
95% confidence inter-
val
20
8—37
14
4—32
31
9—62
20
4—48
having recurring lesions are not outdoor workers;
some are very indoor-type women who avoid the
sun. Their current lesions can surely have
nothing to do with their current relations with
sunlight, and so they can add only random error
to our study. Their inclusion may, however, be
worth while from the standpoint of administra-
tive simplicity and integrity of the study.
As for the present state of our sequential
analysis of results, it is of course much too early
to be able to detect anything short of a miracle,
and this, as anticipated, has failed to occur. The
new lesion rates in the two contrasting drug
groups are still running within statistical limits
of being the same. If an overall impression is
desired, I would say that our impression is that
the human if properly treated is a marvelously
cooperative experimental subject. See Table 2.
Because our study is still very much in process
and depends vitally on the maintenance of cer-
TABLE 1
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tam confidences, I have been deliberately vague
and evasive about certain details of the trial,
including the identities of my splendid col-
laborators. We particularly desire no publicity
whatever on this project. All we have at present
is a highly speculative hypothesis, plus a well or-
ganized experiment which, if severely left alone
for a couple of years may give us an answer.
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